Nintx (Next Innovative Therapeutics) was originated in Brazil at the beginning of 2021 to translate complex biological interactions (plants, microorganisms, and humans) into novel therapies with environmental and social impact. To that end, Nintx has established partnerships with research institutes, private companies and investment funds that bring both complementary expertise and financial resources.
Nintx develops a new generation of medicines leveraging biodiversity, primarily from Brazil, targeting multifactorial diseases, caused by genetic and environmental factors as well as their interactions via the human gut microbiome. Nintx owns cutting-edge proprietary technologies, an Agentic AI platform (GAIApath®) and an artificial gut (xGIbiomics®), that enable the development of innovative ingredients (pharmaceuticals and nutraceuticals).
Company Details
- Employees
- 15
- Founded
- -
- Address
- Avenida Das Nações Unidas 18801,, 18801,brazil
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.nintx.com.br
- Keywords
- R&D, Medicinal Chemistry, Computational Chemistry, Advanced Analytical Technologies, Formulation, Metagenomics, Metabolomics, Scale Up.
- HQ
- São Paulo, SP
Nintx Questions
Nintx's website is http://www.nintx.com.br
Nintx's LinkedIn profile is https://br.linkedin.com/company/nintx
Nintx has
15 employees.
View email and phone details for 15
employees at Nintx.
Nintx's industry is
Biotechnology Research
Nintx's top competitors are
Beep Saúde,
Pitanga,
Sami,
Conexa Saúde,
Mevo,
Vittude,
Livance,
Pipo Saúde,
Alice,
Centro De Inovação E Ensaios Pré-Clínicos (Cienp).
Nintx's categories are Biotechnology Research
Nintx's founding year is 2021
